PLEASE NOTE CHANGE TO OCTOBER 5, 2012
Patients, parents and families – please join us next Friday by teleconference to learn more about this exciting mitochondrial disease clinical trial.
Results from the Edison Pharma EPI-743 Phase 2A Leigh Syndrome Trial: An update with Dr. Miller and Dr. Enns
Join us for a very important discussion about the recent news from Edison Pharma regarding the EPI-743 trial for children with Leigh Syndrome. In mid-September, Edison announced positive results of their Phase 2A clinical trial for children with Leigh Syndrome conducted in Rome, Italy. All children treated showed reversal of disease progression. Following this unprecedented news, the results were published online in the September 10 publication of the journal of Molecular Genetics and Metabolism. At the same time, Edison announced that EPI-743 had received orphan drug designation from the European Medicines Agency (the European equivalent of the US Food & Drug Administration).
Dr. Greg Enns from Lucille Packard Children’s Hospital at Stanford University and Dr. Guy Miller, physician and CEO of Edison Pharma will offer an explanation of the exciting progress of EPI-743 as well as answer your questions via a live teleconference on Friday, October 5th.
Topics for this call include:
What is EPI-743 and who has been treated so far?
What do the results from the Phase 2A trial mean for the mitochondrial disease patient community?
Who is currently eligible for treatment by EPI-743?
What does orphan drug designation mean, and how does it impact the availability of EPI-743?
What does the data demonstrate about safety and effect on mitochondrial disease symptoms for those who were treated by EPI-743?
What should interested patients and families do to become involved in this trial?
Where can physicians and families go for more information?
Join us in this special teleconference offered in collaboration
Friday, October 5th at 9 am PDT/12 pm EDT
To join the online event
1.Click hereto join the online event.
Or copy and paste the following link to a browser:
2. Click “Join Now”.
To join the teleconference only
Call-in toll-free number (US/Canada): 1-855-244-8681
Call-in toll number (US/Canada): 1-650-479-3207
Global call-in numbers:https://umdf.webex.com/umdf/globalcallin.php?serviceType=EC&ED=103986082&tollFree=1
Toll-free dialing restrictions:http://www.webex.com/pdf/tollfree_restrictions.pdf
Access code: 666 532 607
Please send questions in advance firstname.lastname@example.org@umdf.org